Agendia and Ferrer Enter Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets

Agendia BV and Ferrer inCode have announced an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services; MammaPrint®, a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint, a gene expression profiling service which offers a method of identifying the primary tumor site in Cancer of Unknown Primary (CUP).

Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain.

"We are confident that Ferrer inCode is the right partner for the successful expansion of MammaPrint and CupPrint into these additional European markets," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This agreement will allow us to increase the availability of our services to more customers in these countries, with the result being that more patients and their physicians will have access to the valuable information provided by these tests."

According to Agendia, the MammaPrint is a clinically proven, accurate gene expression profiling test that offers healthcare professionals a unique personalized prognostic analysis to determine a patient's individual risk of recurrence of breast cancer. CupPrint is a diagnostic service that identifies the origin of the primary tumor in Cancer of Unknown Primary, which accounts for up to five percent of all new cancer referrals and is the fourth most common cause of cancer mortality worldwide.